Current-law scope and cautions
- China does not provide a nationwide blanket exemption allowing all hospitals to use unregistered LDTs. Current pilots/special pathways are institution-, region- and test-specific.
- Clinical need, in-house development/use, validation, quality management and restricted distribution are core controls.
- Verify the latest NMPA/NHC and provincial pilot documents before relying on the result.
Use: This is a screening/estimation tool, not a legal opinion. Confirm the latest primary authority, regulator practice, local rules and transaction documents before acting.
